(NASDAQ: ALKS) Alkermes's forecast annual revenue growth rate of 7.15% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.15%.
Alkermes's revenue in 2026 is $1,753,599,000.On average, 22 Wall Street analysts forecast ALKS's revenue for 2026 to be $312,729,027,940, with the lowest ALKS revenue forecast at $293,908,151,460, and the highest ALKS revenue forecast at $325,332,293,440. On average, 22 Wall Street analysts forecast ALKS's revenue for 2027 to be $332,558,165,660, with the lowest ALKS revenue forecast at $297,941,196,420, and the highest ALKS revenue forecast at $388,516,664,480.
In 2028, ALKS is forecast to generate $364,822,525,340 in revenue, with the lowest revenue forecast at $313,737,289,180 and the highest revenue forecast at $475,395,174,660.